Citation Impact
Citing Papers
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
2009
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo
2009
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Treatment of kidney cancer
2009 StandoutNobel
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
Smarter drugs emerging in pancreatic cancer therapy
2014
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
2006
Idiopathic pulmonary fibrosis
2017 Standout
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
The role of FLT3 in haematopoietic malignancies
2003
Flt3 Signaling-Dependent Dendritic Cells Protect against Atherosclerosis
2011 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Hepatocellular carcinoma
2018 Standout
The discovery of receptor tyrosine kinases: targets for cancer therapy
2004
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
2004
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
2003 StandoutNobel
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Cancer genes and the pathways they control
2004 Standout
Killing time for cancer cells
2005
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
2011
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
2009 StandoutNobel
The Molecular Basis of Leukemia
2004
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
2008
Nasopharyngeal carcinoma
2015 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
2010
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
2007
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
2004
Cancer immunotherapy comes of age
2011 StandoutNature
Molecular basis for sunitinib efficacy and future clinical development
2007
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507
2013
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
2009
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Receptor tyrosine kinases in normal and malignant haematopoiesis
2003
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
2009
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma
2010
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hepatocellular Carcinoma
2019 Standout
I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development
2010 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Acute Myeloid Leukemia
2015 Standout
Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy
2016
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes
2012 StandoutNobel
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
2008
Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity
2005
Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells
2010 StandoutNobel
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
2004
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
2008
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
2003
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
The role of microRNA genes in papillary thyroid carcinoma
2005 Standout
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
2005
Sunitinib: From Rational Design to Clinical Efficacy
2007
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
2006
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer
2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
2005
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
2005
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4
2013 StandoutNobel
Multiple Myeloma
2011 Standout
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
2009
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2008
A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer
2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Tinya J. Abrams being referenced
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
2003
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
2003
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
2003
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
2003
CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice
2006
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
2003